News | February 11, 2021
Sun Pharma Advanced Research Q3FY21 loss at Rs. 67.62 crore
The company posted net loss of Rs. 55.51 crores for the period ended December 31, 2019.
The company posted net loss of Rs. 55.51 crores for the period ended December 31, 2019.
The company has reported total income of Rs.25699.68 crores during the 9 months period ended December 31, 2020.
Positive volume growth was observed in key therapies such as respiratory (13.2% yoy), anti-neoplastics (12.1% yoy) and cardiac (4.8% yoy) during September 2025
Ukhade brings deep expertise in large-scale infrastructure planning, cross-functional leadership, and project innovation.
The wholly owned subsidiary will carry on the business of all types of research and development and other related services
The IND application supports the next phase of development of SBO-154
These results represent critical milestones for Philogen, as Fibromun has the potential to become second product to successfully complete multinational clinical trials with registration potential
SPARC to receive 55% equity in Tiller Therapeutics
The product will be marketed by Dr. Reddy's
He recently served as Senior Vice President of the API business at Shilpa Pharma Life Sciences for over 3 years
Subscribe To Our Newsletter & Stay Updated
